Domestic product approval for an adult atopic dermatitis treatment developed by LEO Pharma, a Danish pharmaceutical company, is imminent. According to the pharmaceutical industry on the 8th, the Ministry of Food and Drug Safety completed the safety and efficacy review of 'Adtralza 150mg (tralokinumab)', which Leo Pharma applied for.

As the safety and efficacy review of the Ministry of Food and Drug Safety has been completed, it is expected to enter the item approval process soon. This drug is a component of tralokinumab and is sold under the trade names of Adbry in the US and Adtralza in Europe.

Adtralza is the first biological agent that specifically binds to and inhibits IL-13 cytokine,